JP2014534219A5 - - Google Patents

Download PDF

Info

Publication number
JP2014534219A5
JP2014534219A5 JP2014539008A JP2014539008A JP2014534219A5 JP 2014534219 A5 JP2014534219 A5 JP 2014534219A5 JP 2014539008 A JP2014539008 A JP 2014539008A JP 2014539008 A JP2014539008 A JP 2014539008A JP 2014534219 A5 JP2014534219 A5 JP 2014534219A5
Authority
JP
Japan
Prior art keywords
cancer
combination
combination according
patient
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539008A
Other languages
English (en)
Japanese (ja)
Other versions
JP6138140B2 (ja
JP2014534219A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/061952 external-priority patent/WO2013063286A1/en
Publication of JP2014534219A publication Critical patent/JP2014534219A/ja
Publication of JP2014534219A5 publication Critical patent/JP2014534219A5/ja
Application granted granted Critical
Publication of JP6138140B2 publication Critical patent/JP6138140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539008A 2011-10-25 2012-10-25 癌患者の治療 Active JP6138140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551138P 2011-10-25 2011-10-25
US61/551,138 2011-10-25
PCT/US2012/061952 WO2013063286A1 (en) 2011-10-25 2012-10-25 Treatment of patients suffering from cancer

Publications (3)

Publication Number Publication Date
JP2014534219A JP2014534219A (ja) 2014-12-18
JP2014534219A5 true JP2014534219A5 (https=) 2015-10-29
JP6138140B2 JP6138140B2 (ja) 2017-05-31

Family

ID=47146725

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014539008A Active JP6138140B2 (ja) 2011-10-25 2012-10-25 癌患者の治療

Country Status (4)

Country Link
US (1) US20140378404A1 (https=)
EP (1) EP2771034B1 (https=)
JP (1) JP6138140B2 (https=)
WO (1) WO2013063286A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104813167B (zh) 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8519452D0 (en) * 1985-08-02 1985-09-11 Erba Farmitalia Injectable solutions
CA2462376C (en) * 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
ES2629696T3 (es) * 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
TWI426905B (zh) 2006-02-09 2014-02-21 安龍製藥公司 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
JP2010536738A (ja) * 2007-08-16 2010-12-02 バイオコンパティブルズ ユーケー リミテッド 薬剤の組み合わせの送達
ME03396B (me) * 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek

Similar Documents

Publication Publication Date Title
CY1123739T1 (el) Αντισωματα anti-cd38
JP2017506264A5 (https=)
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
JP2016538344A5 (https=)
NZ603155A (en) Phospholipid drug analogs
MX379539B (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
UA117072C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським
MX2014004862A (es) Formulaciones de polimero acrilico.
EA201290807A1 (ru) Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы
NZ706836A (en) Methods of treating cancer
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
MX367403B (es) Diesteres de fosfonato nucleosido aciclico.
EA201391171A1 (ru) Формы рифаксимина и их применение
PH12015501088A1 (en) Dimeric compounds
EP3453714A3 (en) Cardenolide and bufadienolide 3-carbonate and 3-carbamate derivatives for the treatment of cancer and compositions thereof
RU2014117707A (ru) Способ лечения пролиферативного заболевания
WO2013040227A3 (en) Therapeutic compounds
WO2013023043A3 (en) Treatment of advanced solid tumors using combination of anti-erbb3 immunotherapy and selected chemotherapy
PH12013502663A1 (en) Dosage administration of anti-erbb3 antibodies in combination with paclitaxel for treatment of gynecological cancers
CY1118596T1 (el) Θεραπευτικος και διαγνωστικος στοχος
CY1120395T1 (el) Παραγωγα στερολης και χρηση αυτων για την αγωγη νοσηματων που περιλαμβανουν μετασχηματισμενα αστροκυτταρα ή για την αγωγη κακοηθων αιμοπαθειων
GB201116017D0 (en) Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors
PH12015500399A1 (en) Azaindolines
JP2014534219A5 (https=)
JP2017502091A5 (https=)